Navigation Links
Aflac Japan To Offer Cancer Insurance Product Through Japan Post
Date:11/16/2007

COLUMBUS, Ga., Nov. 16 /PRNewswire-FirstCall/ -- Aflac Incorporated announced today that Japan Post Network Co., Ltd., a subsidiary of Japan Post Holdings Co., Ltd., has selected Aflac Japan as the exclusive provider of cancer insurance for distribution through the nationwide postal office network.

Japan Post Network Co. is one of four separate postal entities that began operating in October 2007 as a part of the postal privatization process set forth under laws enacted in 2005. Japan Post Network Co. operates approximately 24,000 post office locations throughout Japan.

Commenting on the announcement, Aflac Incorporated Chairman and Chief Executive Officer Daniel P. Amos said: "We are very pleased that Japan Post chose our cancer insurance product for sale through its extensive network. We believe Japan Post's selection of Aflac reflects the quality of our newly introduced Cancer Forte product, the overall strength of the Aflac brand, a reputation for quality customer service and the support we provide to our sales force. Although Japan Post has not yet established a specific time frame for sales to commence, we anticipate that sales should occur sometime in 2008."

Amos added: "Throughout 2007, we have been encouraged by the overall direction of Aflac Japan's new annualized premium sales. We continue to believe that our sales will be flat to up 4% in the second half of 2007. And although we have not yet finalized our marketing plans and objectives for 2008, our preliminary expectation is that Aflac Japan's sales should increase 3% to 7% next year."

For more than 50 years, Aflac products have given policyholders the opportunity to direct cash where it is needed most when a life-interrupting medical event causes financial challenges. Aflac is the number one provider of guaranteed-renewable insurance in the United States and the number one insurance company in terms of individual insurance policies in force in Japan. Our insurance products provide protection to more than 40 million people worldwide. Aflac has been included in Fortune magazine's listing of America's Most Admired Companies for seven consecutive years and in Fortune magazine's list of the 100 Best Companies to Work For in America for nine consecutive years. Aflac has also been recognized three times by both Fortune magazine's listing of the Top 50 Employers for Minorities and Working Mother magazine's listing of the 100 Best Companies for Working Mothers. Aflac Incorporated is a Fortune 500 company listed on the New York Stock Exchange under the symbol AFL. To find out more about Aflac, visit aflac.com.

The Private Securities Litigation Reform Act of 1995 provides a "safe harbor" to encourage companies to provide prospective information, so long as those informational statements are identified as forward-looking and are accompanied by meaningful cautionary statements identifying important factors that could cause actual results to differ materially from those included in the forward-looking statements. We desire to take advantage of these provisions. This document contains cautionary statements identifying important factors that could cause actual results to differ materially from those projected herein, and in any other statements made by company officials in communications with the financial community and contained in documents filed with the Securities and Exchange Commission (SEC).

Forward-looking statements are not based on historical information and relate to future operations, strategies, financial results or other developments. Furthermore, forward-looking information is subject to numerous assumptions, risks, and uncertainties. In particular, statements containing words such as "expect," "anticipate," "believe," "goal," "objective," "may," "should," "estimate," "intends," "projects," "will," "assumes," "potential," "target," or similar words as well as specific projections of future results, generally qualify as forward-looking. Aflac undertakes no obligation to update such forward-looking statements.

We caution readers that the following factors, in addition to other factors mentioned from time to time could cause actual results to differ materially from those contemplated by the forward-looking statements: legislative and regulatory developments; assessments for insurance company insolvencies; competitive conditions in the United States and Japan; new product development and customer response to new products and new marketing initiatives; ability to attract and retain qualified sales associates and employees; ability to repatriate profits from Japan; changes in U.S. and/or Japanese tax laws or accounting requirements; credit and other risks associated with Aflac's investment activities; significant changes in investment yield rates; fluctuations in foreign currency exchange rates; deviations in actual experience from pricing and reserving assumptions including, but not limited to, morbidity, mortality, persistency, expenses, and investment yields; level and outcome of litigation; downgrades in the company's credit rating; changes in rating agency policies or practices; subsidiary's ability to pay dividends to parent company; ineffectiveness of hedging strategies; catastrophic events; and general economic conditions in the United States and Japan.

(Logo: http://www.newscom.com/cgi-bin/prnh/20041202/CLTH019LOGO )

Analyst and investor contact - Kenneth S. Janke Jr., 800.235.2667 - option 3, FAX: 706.324.6330, or kjanke@aflac.com.

Media contact - Laura Kane, 706.596.3493, FAX: 706.320.2288, or lkane@aflac.com.


'/>"/>
SOURCE Aflac Incorporated
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Aflac Announces Resignation of U.S. Marketing Officer
2. Aflac Incorporated to Release Third Quarter Results On October 23, 2007
3. Aflac Incorporated Announces Third Quarter Results, Declares Fourth Quarter Cash Dividend
4. Aflac Honors Hispanic Entrepreneurs Making a Difference in Texas
5. ESMO, Oxford Journals and the Japanese Society of Medical Oncology announce collaboration
6. Stille and Enova Form Strategic Partnership to Introduce Worlds Brightest LED Cordless Surgical Headlights Into Europe and Japan
7. ImClone and Bristol-Myers Squibb Announce Joint Agreement With Merck KGaA to Co-Develop and Co-Commercialize ERBITUX(R) in Japan
8. Keiko Hattori Joins Haemonetics as President of Haemonetics Japan
9. Mannatech Hosts Japan National Convention
10. STAAR Surgical to Purchase Canons Interest in Japanese Joint Venture
11. Abaxis Announces Appointment of New Distribution Partner in Japan
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/6/2016)... Greifensee, Switzerland (PRWEB) , ... December 06, 2016 ... ... Library, a one-stop portal for all the knowledge resources, including white papers, ... instructions, certificates, and more. , To access more than 9,000 documents, webinars ...
(Date:12/6/2016)... ... ... 'Tis the season for family, festivity, food and fun! Temptation abounds, and ... eating healthy, staying active, and taking medication and doing daily foot health checks (a ... "Shopping trips, parties and family gatherings can take their toll on our feet during ...
(Date:12/6/2016)... ... December 06, 2016 , ... Specialty ... newly updated International Audit Protocol Consortium (IAPC) EHS audit protocol for Great ... understand the scope of their EHS regulatory obligations and rapidly collect, share, archive, ...
(Date:12/6/2016)... Aliso Viejo, California (PRWEB) , ... December 06, 2016 , ... ... which allows users to flicker, flash, and flare from clip to clip with high ... , TransFlare 4K Jewel contains 44 lens flares filmed on the RED ...
(Date:12/5/2016)... ... December 05, 2016 , ... "FCPX Overlay Glare is a tool that ... without heavy rendering or complicated compositing," said Christina Austin - CEO of Pixel Film ... organic spectrum of lights that simulates the look of a glare. Just drag ...
Breaking Medicine News(10 mins):
(Date:12/6/2016)... , Dec. 6, 2016 Eurofins ... accreditation from the College of American Pathologists (CAP) ... (CLIA) for its new laboratory in ... moved its North American headquarters. "Our ... sequencing -- which is still considered the ,Gold ...
(Date:12/6/2016)... Miss. , Dec. 6, 2016 Two ... rescue personnel in a simulated mass casualty event Tuesday ... . The technology debuted before an audience including ... and representatives from Homeland Security, Federal Law Enforcement ... Drone Project, known as HiRO (Health Integrated Rescue Operations), ...
(Date:12/6/2016)...  Arcturus Therapeutics, Inc. ("Arcturus" or the "Company"), ... it entered into collaboration with Takeda Pharmaceutical Company ... of NASH and other gastrointestinal (GI) related disorders, ... UNA Oligomer chemistry. The financial terms were not ... and expertise in GI disorders, we are confident ...
Breaking Medicine Technology: